Remedy Plan Therapeutics – a privately-held clinical-stage pharmaceutical company developing novel and hyperbolic NAMPT inhibitors – announced the company has raised over $18 million in an oversubscribed insider financing round. The funding round includes participation from Schooner Capital and Alexandria Venture Investments. This brings the company’s total funding to date to $55 million.
The funding will accelerate the advancement of the company’s first-in-class NAMPT inhibitor, RPT1G, into a Phase 1/2 clinical study in patients with AML or high-risk MDS. And this builds on the momentum of an ongoing first-in-human study in healthy adults (NCT06667765), which will conclude later this month.
NAMPT is a critical enzyme controlling how cells use energy and is core to human biology. Its dysregulation has been linked to over 20 diseases, making it a high-value therapeutic target for biopharma drug development. And RPT1G is the first well-tolerated NAMPT inhibitor, avoiding on-target toxicities that have hampered the development of prior NAMPT inhibitors by others.
What the funding will be used for: The funding will also support the continued development of Remedy Plan’s pipeline of NAMPT inhibitors with applications across solid tumors, autoimmune diseases, and obesity.
KEY QUOTES:
“Pharma companies have been trying to unlock the NAMPT target for over 25 years, and we have finally cracked it. We are eager to advance RPT1G into Phase 1/2 clinical studies for patients with AML/MDS, for which few treatment options exist. This funding not only allows us to sprint toward that goal, but also allows us to further develop our pipeline of novel NAMPT inhibitors for use in other diseases.”
Greg Crimmins, Ph.D., Founder and CEO of Remedy Plan
“We continue to be impressed by Remedy Plan’s differentiated scientific approach and the potential of hyperbolic NAMPT inhibition. We believe the company is well-positioned to create significant value by addressing key unmet needs in oncology, autoimmunity, and obesity with their pipeline of unique NAMPT inhibitors.”
Alexandra Manick, Principal at Schooner Capital
